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ORIGINAL ARTICLE
Quality of Life Assessment in Korean Patients 
with Pemphigus
Jae Yong Sung, Mi Ryung Roh, Soo-Chan Kim
Department of Dermatology and Cutaneous Biology Research Institute, Gangnam Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea
Background: Measuring the quality of life (QOL) is important 
in the evaluation of nonclinical aspects of diseases, for the 
discovery of functional and psychological limitations, and in 
choosing treatment in the initial phase of the disease. 
Pemphigus is a potentially fatal autoimmune bullous disease 
caused by autoantibodies against desmogleins (cadherin 
family proteins in desmosomes). Thus far, there has been no 
published study on QOL in Korean patients with pemphigus. 
Objective: To study the impact of pemphigus on the QOL in 
a large number of Korean patients. Methods: Sixty-six pa-
tients enrolled at the Gangnam Severance Hospital from 
March 2012 to March 2013 were assessed for QOL by using 
the Dermatology Life Quality Index (DLQI), and for anxiety 
and depression by using the General Health Questionnaire 
(GHQ). Spearman’s rank-order correlation, t-test, and ANOVA 
were used to identify the relations between the DLQI score 
and other clinical variables. Results: Pemphigus vulgaris and 
pemphigus foliaceus significantly reduced the QOL of pa-
tients. The average DLQI score for all patients was 10.18. The 
mean DLQI score was 13.45 in patients in the active state and 
5.15 in the patients in the remission state. The DLQI score 
highly correlated with disease severity, titer of anti-desmo-
glein 1 in enzyme-linked immunosorbent assay, and the cor-
ticosteroid dose. However, the QOL was not affected by sex, 
age, subtype of pemphigus, duration of disease, or comor-
bidities. Forty-two percent of the patients showed a positive 
result in the GHQ, reflecting probable minor psychiatric 
nonpsychotic conditions, and the GHQ score positively cor-
related to the DLQI score. Conclusion: Pemphigus signifi-
cantly impairs the QOL of patients. The QOL of Korean pem-
phigus patients significantly correlates with clinical severity. 
Therefore, considerable attention should be paid to the pa-
tients’ QOL and psychological states as well as clinical 
status. (Ann Dermatol 27(5) 492∼498, 2015)
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INTRODUCTION
There are many definitions for the term “quality of life” 
(QOL). The World Health Organization has defined QOL 
as individuals’ perceptions of their position in life in the 
context of the culture and value systems in which they 
live, and in relation to their goals, expectations, standards, 
and concerns1. The QOL includes the physical, functional, 
social, and emotional well-being of a person. In addition, 
measuring the QOL is important when evaluating the ben-
efits and harms of a treatment. It is also used for the im-
provement of the doctor-patient relationship. Therefore, in 
recent years, dermatologists have leaned toward using 
QOL measures as an adjunct to the clinical assessment of 
diseases, as a secondary outcome in clinical practice2. 
Although skin diseases are rarely life-threatening, their im-
pact on the QOL can be major. For instance, the impact of 
psoriasis on the QOL has been found to be comparable to 
the impact of heart failure3. 
Pemphigus is a rare but severe autoimmune bullous dis-
ease caused by autoantibodies directed against desmo-
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gleins, and it is clinically characterized by bullae and 
painful erosions of the skin and mucous membranes4. The 
different types of pemphigus can be distinguished by the 
specificity of autoantibodies to different targets or by the 
location of blister formation. Generally, pemphigus can be 
divided into two major forms: pemphigus vulgaris (PV) 
and pemphigus foliaceus (PF). Patients with PV, which is 
associated with autoantibodies against desmoglein 3 and 
1, have mucous membrane erosions and/or cutaneous 
blisters. PF patients exclusively have cutaneous blisters 
without mucosal lesion and are associated with autoanti-
bodies against desmoglein 1. Other subtypes of the pem-
phigus group include paraneoplastic pemphigus, IgA pem-
phigus, and drug-induced pemphigus.
Until now, there have been only a few published studies 
on the QOL in patients with pemphigus5-12. All of these 
studies have demonstrated a great impact on the QOL and 
psychological status of pemphigus patients. In particular, 
patients with severe skin and mucosal involvement experi-
ence a more impaired QOL than others. The aim of this 
study is to determine the QOL in a large number of 
Korean patients with pemphigus. In this study, we used 
the Dermatology Life Quality Index (DLQI) and the Gene-
ral Health Questionnaire (GHQ) to evaluate the QOL and 
psychological status of each patient.
MATERIALS AND METHODS
Study design
A single-center, cross-sectional study was performed from 
March 2012 to March 2013 at the Department of Derma-
tology, Gangnam Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea. Informed consent was 
obtained from all patients after providing them with writ-
ten and oral information. The study was approved by the 
institutional review board of the Gangnam Severance 
Hospital (IRB No. 3-2012-0012).
Patients
The criteria for patient selection were as follows: patients 
with PV or PF whose diagnoses were confirmed by clin-
ical features, pathology, and direct immunofluorescence 
findings; patients who were able to provide written infor-
med consent; patients aged 16 years or older; patients 
able to read the Korean language; and patients who did 
not have any severe dermatological, mental, or physical 
illness.
The information collected included personal data (e.g., 
age, sex, body mass index, marital status, educational lev-
el, employment status, number of children, and history of 
cigarette smoking or alcohol use), clinical data (e.g., co-
morbidities, date of onset, clinical subtype, and clinical 
activity of disease), Pemphigus Disease Area Index (PDAI) 
score, immunological data concerning autoantibodies, 
and prescribed treatment. 
Concerning disease activity, we used the consensus state-
ment on the definition of disease activity and therapeutic 
response proposed by the International Pemphigus Com-
mittee in 200813. The definitions of complete remission 
and partial remission are the absence of new or estab-
lished lesions for at least 2 months and the presence of 
transient new lesions that heal within 1 week, respec-
tively.
Patients were examined by two dermatologists to assess 
the disease severity by using the PDAI scoring system, 
which was developed by the International Pemphigus 
Definition Committee13. This scoring system has three 
components relating to the skin, scalp, and mucous mem-
branes. In the skin assessment, 12 anatomic sites (ears, 
nose, face, neck, chest, abdomen, back and buttocks, 
arms, hands, legs, feet, and genitals) are reviewed and as-
signed a score according to the following disease extent: 0 
(no lesions), 1 (1∼3 lesions, all ≤6 cm; up to 1 lesion 
＞2 cm), 2 (2∼3 lesions, all ≤6 cm; at least 2 lesions ＞2 
cm), 3 (＞3 lesions, all ≤6 cm), 5 (＞3 lesions and/or 1 le-
sion ＞6 cm), or 10 (＞3 lesions and/or at least 1 lesion 
＞16 cm). The scalp is assigned a score based on the pres-
ence of bullae, erosions, or new erythema of 0 (no activ-
ity), 1 (one quadrant affected), 2 (two quadrants affected), 
3 (three quadrants affected), 4 (whole scalp affected), or 
10 (at least 1 lesion ＞6 cm). Mucosal activity is assessed 
by reviewing 12 mucosal sites (eyes, nose, buccal, hard 
palate, soft palate, upper gingiva, lower gingiva, tongue, 
floor of the mouth, labial mucosa, posterior pharynx, and 
anogenitalia) and assigning a score based on the presence 
of erosions and blisters as follows: 0 (absent), 1 (1 lesion), 
2 (2∼3 lesions), 5 (＞3 lesions or 2 lesions ＞2 cm), or 10 
(entire area). The total possible score for the PDAI ranges 
from 0 to 130 for the skin score (120 points for body, 10 
points for scalp) and up to 120 points for mucosal activity.
Questionnaires
The DLQI is one of the most frequently used QOL meas-
ures in dermatology. It consists of 10 questions and is de-
signed for use in adults older than 16 years. The questions 
are classified in the following subscales: symptoms and 
feelings (questions 1 and 2), daily activities (questions 3 
and 4), leisure (questions 5 and 6), personal relationships 
(questions 8 and 9), work and school (question 7), and 
treatment (question 10). The DLQI score is calculated by 
summing the scores of the 10 questions. The maximum 
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Table 1. Dermatology Life Quality Index (DLQI) category scores in 66 pemphigus patients
Categories of DLQI
Mean DLQI score of 
the active group (n=40)
Mean DLQI score of 
the remission group (n=26)
Mean DLQI score of 
all patients (n=66)
Symptoms and feelings (questions 1 and 2) 3.33 1.46 2.59
Daily activities (questions 3 and 4) 2.45 0.65 1.74
Leisure (questions 5 and 6) 2.93 1.38 2.32
Work and school (question 7) 1.13 0.38 0.83
Personal relationships (questions 8 and 9) 2.58 1.00 1.95
Treatment (question 10) 1.05 0.27 0.74
Total DLQI score 13.45 5.15 10.2
Table 2. Correlation between various clinical characteristics and Dermatology Life Quality Index (DLQI) score and General Health
Questionnaire (GHQ)-12 by using Spearman's rank correlation
Clinical characteristic
DLQI GHQ-12
r p-value　 r p-value
Age －0.04 0.740 －0.01 0.911
Body mass index －0.04 0.766 －0.05 0.699
Number of comorbidities 0.05 0.700 －0.04 0.750
Duration of disease －0.19 0.130 －0.19 0.119
PDAI (total) 0.71 ＜0.0001 0.58 ＜0.0001
PDAI (mucous) 0.36 0.003 0.32 0.010
ELISA (anti-desmoglein 1) 0.60 0.001 0.30 0.127
ELISA (anti-desmoglein 3) 0.23 0.279 0.19 0.376
Dose of methylprednisolone 0.70 ＜0.0001　 0.56 ＜0.0001
PDAI: Pemphigus Disease Area Index, ELISA: enzyme-linked immunosorbent assay.
score is 30, and the minimum score is 0. The higher the 
score, the more the QOL is impaired. Grade 1 (0∼1) 
means no effect at all on the patient’s life. Similarly, grade 
2 (2∼5) means small, grade 3 (6∼10) means moderate, 
grade 4 (11∼20) means very large, and grade 5 (21∼30) 
means an extremely large effect on the patient’s life13. In 
this study, we implemented a validated Korean translation 
of the DLQI.
The GHQ-12 is a self-administered 12-item questionnaire 
designed to measure psychological distress and to detect 
current nonpsychotic psychiatric disorders such as depres-
sion and anxiety. Answers are given on a four-point scale. 
When scored with the binary method (0－0－1－1), the 
GHQ-12 can be used as a screening tool to detect minor 
nonpsychotic psychiatric disorders, yielding final scores 
that range from 0 to 12. Operationally, patients scoring ≥
4 are considered “GHQ-positive,” reflecting probable mi-
nor nonpsychotic psychiatric disorders like depression 
and anxiety. 
Statistical analyses
Statistical analyses were performed by using commercial 
software (SAS ver. 9.2; SAS Institute, Cary, NC, USA). De-
scriptive data are presented as numbers with percentages 
and means with standard deviations. Spearman’s rank-or-
der correlation, t-test, ANOVA, and multiple regression 
analysis were used to identify the relations between the 
DLQI score and other clinical variables. Differences were 
defined as statistically significant at p＜0.05.
RESULTS
A total of 66 patients (31 male, 35 female) with an average 
age of 51.1±13.5 years were included. Forty patients had 
PV and 26 patients had PF. The average duration of dis-
ease was 45.7±38.1 months. Forty patients were in the 
active state, and 26 patients were in the remission state.
The average DLQI score for all patients was 10.2±8.8. 
The most impaired element of the QOL was clinical symp-
toms and feelings, whereas treatment was the least affec-
ted. Table 1 shows more details on the different variables 
and DLQI scores.
We observed a positive correlation between the PDAI and 
DLQI scores (r=0.71, p＜0.0001). In addition, the muco-
sal PDAI score was correlated with the DLQI score (r= 
0.36, p=0.003). The dose of the systemic corticosteroid 
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Table 3. Average Dermatology Life Quality Index (DLQI) scores and General Health Questionnaire (GHQ)-12 in 66 pemphigus patients
for different levels of variables of interest
Variables of interest n (%)
DLQI GHQ-12
Total p-value Positivity (%) p-value
Overall 66 (100) 10.18 47.0 
Sex 0.4249 0.4406 
  Male 31 (47.0) 9.26 41.9 
  Female 35 (53.0) 11.00 51.4 
Age (yr) 0.3999 0.6720 
  ≤50 28 (42.4) 11.25 50.0 
  ＞50 38 (57.6) 9.39 44.7 
Pemphigus 0.7705 0.6909 
  Vulgaris 40 (60.6) 9.93 45.0 
  Foliaceus 26 (39.4) 10.58 50.0 
Duration (mo) 0.3998 0.1109 
  ≤24 24 (36.4) 11.92 62.5 
  25∼36 10 (15.2) 10.70 50.0 
  ≥37 32 (48.5) 8.72 34.4 
PDAI total ＜0.0001 0.0005 
  ≤15 43 (65.2) 5.95 32.6 
  ＞15 23 (34.8) 18.09 73.9 
PDAI mucosa 0.0004 0.0047 
  ≤5 47 (71.2) 7.85 36.7 
  ＞5 19 (28.8) 15.95 76.5 
Comorbidities 0.8815 0.4406 
  0 35 (53.0) 10.03 51.4 
  ≥1 31 (47.0) 10.35 41.9 
Treatment (mg) ＜0.0001* 0.0025 
  MPD≤10 20 (30.3) 4.55 15.0 
  MPD＞10 12 (18.2) 14.33 75.0 
  MPD≤10+A 19 (28.8) 8.37 47.4 
  MPD＞10+A 15 (22.7) 16.67 66.7 
Disease activity ＜0.0001 0.0085 
  Active state 40 (60.6) 13.45 60.0 
  Remission state 26 (39.4) 5.15 26.9 
GHQ-12 ＜0.0001
  Negative (GHQ＜4) 35 (53.0) 5.11 
  Positive (GHQ≥4) 31 (47.0) 15.90 　 　
PDAI: Pemphigus Disease Area Index, MPD: methylprednisolone, A: adjuvant immunosuppressive agent. *p=0.0117 between “MPD
≤10” and “MPD＞10”; p=0.0004 between “MPD≤10” and “MPD＞10+A”; p=0.0085 between “MPD≤10+A” and “MPD＞10+A.”
(methylprednisolone [MPD]) showed a strong positive cor-
relation with the DLQI score (r=0.70, p＜0.0001). The tit-
er of anti-desmoglein 1 antibody correlated with DLQI 
score (r=0.60, p=0.001), but that of anti-desmoglein 3 
antibody did not. Other variables showed no statistically 
significant correlation with the DLQI score (Table 2). 
No significant differences in the DLQI score were obser-
ved between PV and PF, sex, or duration of disease (Table 
3). The DLQI scores of PV and PF patients were 9.93 and 
10.58, respectively. Furthermore, there were no signifi-
cant differences in the scores between PV and PF in the 
active state or the remission state. The DLQI scores of PV 
and PF patients in the active state were 12.96 and 14.27, 
respectively, and those in the remission state were 4.87 
and 5.55, respectively. Patients who were treated with a 
higher dose of corticosteroid (＞10 mg MPD) showed a 
statistically significant increase in the DLQI score com-
pared with those with a lower corticosteroid dose. The 
average PDAI score of the lower-dose MPD group was 5.03 
and that of the higher-dose MPD group was 31.96 (p＜ 
0.0001). The use of an adjuvant immunosuppressive agent 
did not significantly affect the QOL of the patients (Table 
3). The clinical activity of the disease also affected the 
DLQI of pemphigus patients (Table 3). Patients who ach-
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ieved partial remission and complete remission showed 
statistically significantly decreased DLQI scores compared 
with patients with active disease (p＜0.0001); however, 
no statistically significant difference was observed bet-
ween patients with partial remission and those with com-
plete remission (p=0.2751). The mean DLQI score of the 
active group was 13.45±9.3, whereas that of the com-
plete and partial remission groups was 5.15±4.8 (Table 
3). We estimated the titer of autoantibodies with enzyme- 
linked immunosorbent assay. The titer of anti-desmoglein 
1 antibody, which was estimated in 27 patients, correlated 
with the DLQI score (r=0.60, p＜0.001); however, the tit-
er of anti-desmoglein 3 antibody, which was estimated in 
25 patients, did not correlate with the DLQI score (r= 
0.23, p＜0.279).
A positive GHQ, reflecting probable minor nonpsychotic 
psychiatric disorders such as depression and anxiety, was 
detected in 47% of the patients. GHQ positivity was asso-
ciated with a higher DLQI score (p＜0.0001). A significant 
GHQ positivity difference was observed between patients 
in the active state and those in the remission state (p= 
0.0085).
DISCUSSION
Pemphigus is a rare, severe, and potentially fatal disease 
with a strong negative effect on both dermatological and 
general health. Despite this serious condition, only a few 
studies on QOL in pemphigus patients have been publi-
shed. Moreover, no QOL study on pemphigus patients in 
Korea has been reported. Therefore, this study is mean-
ingful in that we measured the QOL of Korean pemphigus 
patients and compared the results with the QOL scores re-
ported in other studies.
We decided to use a skin-specific QOL measurement tool, 
the DLQI, to facilitate comparison with other dermato-
logic conditions. The DLQI was derived from patients 
with various skin diseases and provides a simple method 
of scoring the impact of skin disease on the QOL. A high-
er score indicates a greater impairment of the QOL. Heal-
thy persons have an average score of 0.514. Two studies 
used the DLQI for evaluating the QOL of pemphigus pa-
tients6,11. Both of these studies showed a significant de-
crease in the QOL; the DLQI score of each study was 
10±6.6 and 10.98±5.9, respectively. In our study, the 
average DLQI score of pemphigus patients was 10.18± 
8.8, which is similar to that of the previous two studies. One 
study estimated the DLQI score of epidermolysis bullosa 
(EB), which is another life-threatening bullous disease15. The 
mean DLQI score of adult EB simplex patients was 10.7, 
which was similar to that of our pemphigus patients; how-
ever, the score of adult patients with the Hallopeau－
Siemens subtype of dystrophic EB (18.0) was extremely 
higher than that of pemphigus patients. Atopic dermatitis 
and psoriasis are representative chronic dermatologic di-
sorders. Although the QOL scores of these skin diseases 
have been reported variably in each paper, in a recent 
large cohort study, the measured DLQI scores of atopic 
dermatitis and psoriasis were 7.31±5.98 and 5.93±5.66, 
respectively16. Many negative factors, including the mu-
cosal involvement, painful erosive cutaneous lesions, more 
aggressive systemic corticosteroid treatment and its ad-
verse effects, and higher mortality might be the reasons for 
the more impaired QOL in pemphigus patients. 
Terrab et al.7 used the Medical Outcome Study 36-item 
Short-Form Survey (SF-36) questionnaire, which is a ge-
neric QOL measurement tool, to compare the QOL in 30 
pemphigus patients and 60 healthy adults. Pemphigus pa-
tients showed an impaired QOL compared with healthy 
controls, particularly in those with facial involvement and 
a large extent of lesions. Tabolli et al.8 measured the QOL 
of 58 pemphigus patients with the SF-36 and observed sig-
nificantly worse QOL in patients with mucocutaneous in-
volvement, severe pemphigus, and pemphigus of recent 
onset. Paradisi et al.9, who used the SF-36 and Skindex-29 
questionnaires, reported that a more impaired QOL was 
observed in patients who had both mucous and cutaneous 
involvements. In addition, comorbidities and female sex 
were associated with worse QOL. 
In this study, we used the PDAI scoring system to evaluate 
the severity of disease. The PDAI scoring system, which 
was developed by the International Pemphigus Definition 
Committee, has not been used in previous pemphigus 
QOL studies13. The PDAI scoring system is recognized to 
be more reproducible than the Autoimmune Bullous Skin 
Disorder Intensity Score, which is also a widely used se-
verity score index, and is able to detect smaller differen-
ces17. Other crude score indices, such as the Ikeda index 
and Physician's Global Assessment, are not as reliable or 
as accurate as the PDAI17. Like other previous pemphigus 
QOL studies7-9, our study showed that the DLQI score 
highly correlated with the clinical severity of the disease. 
In addition, the mucosal PDAI score, which shows the se-
verity of mucosal involvement, also correlated with the 
DLQI score. Mucosal involvement of the disease is most 
burdensome in pemphigus patients because mucosal le-
sions have a larger impact on the patients’ fundamental 
and essential activities such as speaking and eating. 
Clinical activity as defined by the International Pemphigus 
Committee in 200813 also affects the QOL of pemphigus 
patients. According to the definition, clinical activity is in-
timately associated with disease severity. As mentioned 
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above, clinical severity measured by the PDAI scoring sys-
tem significantly correlated with the QOL of patients. 
Therefore, patients with remission who had few or no skin 
lesions showed more improved QOL than the group who 
had active skin lesions; however, there was no statistical 
difference in the DLQI scores between patients with parti-
al remission and those with complete remission. 
Treatment was one of the major factors that associated 
with the QOL of patients. Patients who were treated with 
low-dose MPD (≤10 mg) showed a higher QOL. This 
may be because severe skin or mucosal involvement re-
quires a high dose of corticosteroid, which can cause vari-
ous adverse effects. We divided the pemphigus patients 
into the lower-dose corticosteroid (≤10 mg) group and 
the higher-dose corticosteroid (＞10 mg) group. The aver-
age PDAI score of the lower-dose corticosteroid group 
was 5.03 and that of the higher-dose corticosteroid group 
was 31.96 (p＜0.0001). These results indicate that the 
dose of corticosteroid correlated to clinical severity. 
Therefore, it is more likely that patients with low-dose cor-
ticosteroid have a higher QOL because of less disease 
activity. All of the patients with adjuvant therapy were 
treated with mycophenolate mofetil (MMF), except for two 
patients, because MMF is known to have a better safety 
profile than other immunosuppressive agents18. The use of 
an adjuvant immunosuppressive agent did not affect the 
QOL of the patients in our study. A recently published 
study also showed no significant difference in QOL im-
pairment between patients who were treated with an ad-
juvant immunosuppressive agent and those who were 
not10. Compared with systemic corticosteroids, the dose of 
MMF showed less correlation with disease severity. There-
fore, the use of MMF in patients with pemphigus might 
not significantly affect the QOL of the patients.
We expected that the titer of autoantibody will correlate 
with the DLQI score, especially anti-desmoglein 3 anti-
body, which is a main cause of mucosal involvement. 
Both the titers of anti-desmoglein 1 and anti-desmoglein 3 
antibodies showed a positive correlation with the DLQI; 
however, there was no statistically significant correlation 
between the titer of anti-desmoglein 3 antibody and the 
DLQI score. The reason for this unexpected result is un-
clear; however, the titer of autoantibody might not finely 
reflect the clinical status.
In this study, the QOL was not affected by sex, age, sub-
type of pemphigus, or duration of disease. Higher DLQI 
scores were observed in patients with a more recent onset 
compared with patients with a longer disease duration, al-
though this difference did not reach statistical significance. 
Tabolli et al.8 pointed out that a recent diagnosis and lim-
ited access to information about the clinical implications 
of pemphigus may dramatically influence the patients’ 
QOL. On the other hand, over time, decreased symptoms 
and a decreased dose of corticosteroid may increase the 
QOL of pemphigus patients.
Previous studies revealed that pemphigus is highly asso-
ciated with psychological problems8,9,11. Although the 
DLQI has been widely used to evaluate the QOL in vari-
ous cutaneous diseases, this index does not fully encom-
pass the emotional and mental health aspects that might 
be affected. Therefore, the GHQ-12 was used to evaluate 
the nonpsychotic psychiatric problems of pemphigus pa-
tients in this study. The prevalence of patients who were 
GHQ positive was 47%, which was very high considering 
that the prevalence in the general population is 10% to 
12%1. The positive rate of GHQ-12 in our patients was 
similar to that of a previous study performed by Paradisi et 
al.9 There are some studies demonstrating that psycho-
logical factors are related to the development of auto-
immune disease19,20. Another interesting finding of this 
study was a positive correlation between the DLQI and 
GHQ-12 scores. We adjusted the PDAI score to exclude 
any influence of clinical severity; however, the DLQI 
score still correlated with the GHQ-12 score (p＜0.0001). 
As this study is not a controlled trial, it is difficult to deter-
mine a cause-effect relation between clinical severity and 
psychological distress. Ghodsi et al.11 reported similar re-
sults to our study and insisted that the QOL was influ-
enced by psychiatric comorbidities. It is unclear whether 
psychological distress contributed to the onset and pro-
gression of pemphigus; however, the psychological states 
of pemphigus patients should be considered during treat-
ment.
This is a cross-sectional study in which patients were ob-
served at a single time point during the course of the di-
sease. This limitation makes it difficult to establish a clear 
cause-effect relation between multiple variables. Additi-
onal long-term follow-up observation should be provided 
to monitor the variation in QOL during treatment and to 
determine other variables that may affect the QOL of pem-
phigus patients.
In conclusion, pemphigus had a significant impact on 
QOL and psychological status. The most important factors 
that affect QOL were found to be the clinical severity of 
pemphigus as measured by the PDAI and the therapeutic 
dose of corticosteroid. Therefore, consideration should be 
given to patients’ QOL and psychological states, as well as 
clinical states, for an effective care and patient satisfaction.
JY Sung, et al
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